NASDAQ
AYLA

Ayala Pharmaceuticals Inc

(NO DISGNOSTIC SUBSTANCES)
LIFE SCIENCES

Prices are adjusted according to historical splits.

Ayala Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$0.6659
Today's High:
$0.7754
Open Price:
$0.7500
52W Low:
$0.574
52W High:
$14.5
Prev. Close:
$0.7500
Volume:
135221

Company Statistics

Market Cap.:
$0.010 billion
Book Value:
1.242
Revenue TTM:
$0.002 billion
Operating Margin TTM:
-1633%
Gross Profit TTM:
$0.001 billion
Gross Profit TTM:
$0.001 billion
Profit Margin:
0%
Return on Assets TTM:
-63.8%
Return on Equity TTM:
-126.7%

Company Profile

Ayala Pharmaceuticals Inc had its IPO on 2020-05-08 under the ticker symbol AYLA.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Ayala Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Ayala Pharmaceuticals Inc opened at $0.75 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $0.67 - $0.78, and closed at $0.69.

This is a -8.67% slip from the previous day's closing price.

A total volume of 135,221 shares were traded at the close of the day’s session.

In the last one week, shares of Ayala Pharmaceuticals Inc have slipped by -31.5%.

Ayala Pharmaceuticals Inc's Key Ratios

Ayala Pharmaceuticals Inc has a market cap of $0.010 billion, indicating a price to book ratio of 0.641 and a price to sales ratio of 4.482.

In the last 12-months Ayala Pharmaceuticals Inc’s revenue was $0.002 billion with a gross profit of $0.001 billion and an EBITDA of $-0.037 billion. The EBITDA ratio measures Ayala Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ayala Pharmaceuticals Inc’s operating margin was -1633% while its return on assets stood at -63.8% with a return of equity of -126.7%.

In Q2, Ayala Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95%.

Ayala Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-2.714 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ayala Pharmaceuticals Inc’s profitability.

Ayala Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.389 and a EV to EBITDA ratio of 0.231. Its price to sales ratio in the trailing 12-months stood at 4.482.

Ayala Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Ayala Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Ayala Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Ayala Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Ayala Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Ayala Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0.69
52-Week High
$14.5
52-Week Low
$0.574
Analyst Target Price
$8.89

Ayala Pharmaceuticals Inc stock is currently trading at $0.69 per share. It touched a 52-week high of $14.5 and a 52-week low of $14.5. Analysts tracking the stock have a 12-month average target price of $8.89.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Ayala Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Ayala Pharmaceuticals Inc is AYLA

The IPO of Ayala Pharmaceuticals Inc took place on 2020-05-08

Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))

Last Price
Chg
Chg%
$0.41
0
+0.75%
$0.7
-0.06
-7.89%
$0.82
0.06
+7.76%
$0.02
-0.06
-78.67%
$20.01
0
0%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapies for patients suffering from rare and aggressive cancers. The company is headquartered in Rehovot, Israel.

Address

1313 N. MARKET STREET, SUITE 5100, WILMINGTON, DE, US